louisiana glp-1 gastroparesis law office semaglutide legal team in lawsuit gastroparesis louisiana Ozempic Lawsuit for Gastroparesis louisiana Louisiana Ozempic Lawyer | Injury

The effect on stroke is remarkable (and was significant in the trials of both semaglutide and dulaglutide), amounting to an 18% risk reduction, also because the other class of new antidiabetic agents with cardiovascular benefits, the SGLT2-inhibitors, show no a similar effect on stroke (but do have a significant effect on heart failure) [24]

"That broader availability though still limited may be what's driving GLP-1 usage higher overall." Related: Goldman Sachs doubles down on Novo stock target after key event This story was originally published by TheStreet on Jul 8, 2026, where it first appeared in the Health section

Pfizer reported positive Phase 2b results for its investigational ultra long acting GLP 1 receptor agonist, PF 3944, demonstrating continued weight loss after transitioning from weekly to monthly dosing, with no plateau observed at 28 weeks

If you prefer a medication with a dual action on both GLP-1 and GIP receptors, Tirzepatide might be more beneficial

Blood 107(4):1546-1554, 2006